ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health Care • China
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bearish•Quantitative Analysis
•23 Aug 2021 09:29

Hong Kong Connect Flows: Wuxi Biologics, Tencent, Xiaomi Led Outflows

We highlight top three stocks that led the outflows last week were Wuxi Biologics (2269 HK), Tencent (700 HK), and Xiaomi (1810 HK).

Logo
237 Views
Share
•19 Aug 2021 08:53

Asymchem Laboratories (002821.CH) 2021H1 Results - Not Good Enough

This article analyzed Asymchem in terms of its 2021/1H financial results, the comparison with peers, the concerns on growth, the valuation and the...

Logo
290 Views
Share
•11 Aug 2021 09:00

Pre-IPO Asymchem Laboratories - The Strength and the Concerns

The article mainly analyzed Asymchem Laboratories in terms of the industry characteristics, the strength of its business, the comparison with...

Logo
431 Views
Share
bullish•Quantitative Analysis
•02 Aug 2021 11:16

Hong Kong Connect Flows: Inflows into SMIC & Autos

We will highlight weekly top inflows into SMIC (981 HK), Cosco Shipping (1919 HK), Wuxi Biologics (2269 HK), Geely Automobile Holdings Limited (175...

Logo
244 Views
Share
bullish•Quantitative Analysis
•31 Jul 2021 08:00

Asia Shorts: Kuaishou, EDU, Fuyao, Galaxy, KDDI, Sharp, HMC, HMM, SK Tel, Naver, Novatek, Yageo

The Insight looks at large short interest movements across HK, Japan, Korea and Taiwan stocks and highlights large increases/decreases in shorts to...

Logo
331 Views
Share
x